Philippe Corcia

Philippe Corcia

Professor of Neurology

Philippe Corcia is Professor of Neurology and responsible for the ALS Center of the CHU of Tours. This is the only center of the Loire Valley area: in this center, more than 90 new cases are diagnosed every year and the cohort of ALS patients currently exceeds 240 patients. Philippe Corcia is member of the French Neurological Society (SFN), of the European Academy of Neurology and of the panel of the ALS of fronto temporal dementia. He is also member of the ENCALS and TRICALS board and of the Editorial Board of the ALS FTD Journal. He is involved in the scientific committee of the French ALS network (FILSLAN). He was the principal investigator of several clinical trials over the last five years. His field of research is mainly focused on genetic factors and metabolomics in ALS. He is member of the Inserm Unit U1253 iBrain. He signed or co-signed more than 200 publications which mainly dealt with ALS or motor neuron disorders.

Connect
Connect trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial

This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.

Read more
Active
Phase iii

VALOR study

Industry trial

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more